GINKGO BIOWORKS HOLDINGS INC C/WTS 16/09/2026 (TO PUR COM) | 10-Q: FY2025 Q1 Revenue: USD 48.32 M

LB filings
2025.05.06 21:07
portai
I'm PortAI, I can summarize articles.

Revenue: As of FY2025 Q1, the actual value is USD 48.32 M.

EPS: As of FY2025 Q1, the actual value is USD -1.68.

EBIT: As of FY2025 Q1, the actual value is USD -81.58 M.

Cell Engineering Segment

  • Revenue: $38.2 million for the three months ended March 31, 2025, compared to $27.9 million for the same period in 2024, an increase of $10.3 million.
  • Operating Loss: - $31.6 million for the three months ended March 31, 2025, compared to - $92.3 million for the same period in 2024.
  • Research and Development Expenses: $48.7 million for the three months ended March 31, 2025, compared to $81.9 million for the same period in 2024.
  • General and Administrative Expenses: $18.0 million for the three months ended March 31, 2025, compared to $38.2 million for the same period in 2024.

Biosecurity Segment

  • Revenue: $10.1 million for the three months ended March 31, 2025, compared to $10.1 million for the same period in 2024.
  • Operating Loss: - $5.2 million for the three months ended March 31, 2025, compared to - $11.2 million for the same period in 2024.
  • Cost of Biosecurity Revenue: $7.2 million for the three months ended March 31, 2025, compared to $9.2 million for the same period in 2024.

Cash Flow

  • Net Cash Used in Operating Activities: - $51.5 million for the three months ended March 31, 2025, compared to - $89.3 million for the same period in 2024.
  • Net Cash Used in Investing Activities: - $198.7 million for the three months ended March 31, 2025, compared to - $12.1 million for the same period in 2024.

Future Outlook and Strategy

  • Core Business Focus: Ginkgo Bioworks Holdings, Inc. plans to continue its R&D activities under existing and new programs, further invest in its Foundry and Codebase, develop and expand its offerings, and maintain, expand, and protect its intellectual property.
  • Restructuring Actions: The company is undergoing restructuring actions, including workforce reductions and facility consolidations, which are expected to be substantially completed in 2025.
Source: LB filings The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.